World Journal of Urology

, Volume 30, Issue 4, pp 495–503

Novel options for the treatment of castration-resistant prostate cancer

Authors

    • Department of UrologySaarland University
  • Axel S. Merseburger
    • Department of UrologyHannover Medical School
  • Henrik Suttmann
    • Urologikum Hamburg
  • David Schilling
    • Department of UrologyEberhard-Karls-University
  • Lutz Trojan
    • Department of Urology, Medical Faculty MannheimUniversity of Heidelberg
  • Carsten Kempkensteffen
    • Department of UrologyCharité, University Medicine Berlin
  • Stefan Corvin
    • Fachzentrum für Urologie Eggenfelden
  • Michael J. Mathers
    • PandaMED Remscheid
  • Patrick J. Bastian
    • Urologische Klinik und PoliklinikKlinikum der Universität-Campus Großhadern, Ludwig-Maximilians-Universität München
Invited Review

DOI: 10.1007/s00345-011-0796-7

Cite this article as:
Ohlmann, C., Merseburger, A.S., Suttmann, H. et al. World J Urol (2012) 30: 495. doi:10.1007/s00345-011-0796-7

Abstract

Docetaxel had been the only treatment of castration-resistant prostate cancer (CRPC) that demonstrated a survival benefit for the patients. After its approval, no considerable progress has been made for several years until cabazitaxel and abiraterone acetate demonstrated a significant survival benefit in phase III clinical trials. Apart from that several other new drugs appeared including inhibitors of the androgen receptor (MDV3100), endothelin receptor antagonists (atrasentan, zibotentan), bone-targeted drugs (denosumab, Alpharadin) and immunotherapies (sipuleucel-T) capable of improving the prognosis of patients with CRPC. Here, we review the most recent advances in the treatment of CRPC and highlight the most promising new agents currently being investigated in clinical trials.

Keywords

Castration-resistant prostate cancerAbirateroneMDV3100ZibotentanDenosumabAlpharadin

Copyright information

© Springer-Verlag 2011